DK0862633T3 - VP-antigen af JC-virus - Google Patents

VP-antigen af JC-virus

Info

Publication number
DK0862633T3
DK0862633T3 DK96941013T DK96941013T DK0862633T3 DK 0862633 T3 DK0862633 T3 DK 0862633T3 DK 96941013 T DK96941013 T DK 96941013T DK 96941013 T DK96941013 T DK 96941013T DK 0862633 T3 DK0862633 T3 DK 0862633T3
Authority
DK
Denmark
Prior art keywords
virus
antigen
analytical
diagnostic
protein
Prior art date
Application number
DK96941013T
Other languages
English (en)
Inventor
Wolfgang Lueke
Gerhard Hunsmann
Thomas Weber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7778134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0862633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK0862633T3 publication Critical patent/DK0862633T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK96941013T 1995-11-22 1996-11-22 VP-antigen af JC-virus DK0862633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543553A DE19543553B4 (de) 1995-11-22 1995-11-22 VP-Antigene des JC-Virus
PCT/EP1996/005177 WO1997019174A1 (de) 1995-11-22 1996-11-22 Vp-antigene des jc-virus

Publications (1)

Publication Number Publication Date
DK0862633T3 true DK0862633T3 (da) 2005-05-30

Family

ID=7778134

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941013T DK0862633T3 (da) 1995-11-22 1996-11-22 VP-antigen af JC-virus

Country Status (9)

Country Link
US (1) US6238859B1 (da)
EP (1) EP0862633B1 (da)
JP (2) JP4456671B2 (da)
AT (1) ATE288489T1 (da)
CA (1) CA2236159C (da)
DE (2) DE19543553B4 (da)
DK (1) DK0862633T3 (da)
ES (1) ES2237778T3 (da)
WO (1) WO1997019174A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1187928B1 (en) * 1999-06-30 2007-05-23 Evotec AG Virus like particles, preparation and use in screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
WO2005045439A1 (en) * 2003-11-07 2005-05-19 Hepgenics Pty Ltd Binding assay components
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US8124350B2 (en) 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE047230T2 (hu) * 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
IL176377A0 (en) * 2006-06-18 2006-10-05 Ariella Oppenheim Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
WO2008021954A2 (en) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug
US20080057079A1 (en) * 2006-08-31 2008-03-06 Baylor Research Institute JC Virus Vaccine
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
AU2010210979B2 (en) 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HUE061244T2 (hu) * 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere
HUE053664T2 (hu) 2011-07-18 2021-07-28 The United States Of America Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására
EP2548567A1 (en) * 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
PL2774991T3 (pl) 2013-03-06 2018-05-30 Life Science Inkubator Betriebs Gmbh & Co. Kg System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP2926831A1 (en) 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
EP3031820A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
EP3031821A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator polyomavirus VLPs with a fusion protein
EP3368694A1 (en) 2015-10-28 2018-09-05 Life Science Inkubator GmbH Use of vlp for the detection of nucleic acids
EP3670652A1 (en) 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp for the treatment of a lysosomal storage disease
JP6884432B2 (ja) 2018-12-18 2021-06-09 ノイウェイ ファルマ ゲーエムベーハー 新規薬物送達システムおよびそれを提供する方法
JP2023526528A (ja) 2020-05-22 2023-06-21 ノイウェイ ファルマ ゲーエムベーハー 白質ジストロフィーの処置のためのｖｌｐ
WO2025184534A2 (en) * 2024-02-29 2025-09-04 Aera Therapeutics, Inc. Non-enveloped capsid delivery systems and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434383T2 (de) * 1993-03-09 2005-11-24 The University Of Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Also Published As

Publication number Publication date
DE19543553B4 (de) 2009-04-09
JP2007197441A (ja) 2007-08-09
WO1997019174A1 (de) 1997-05-29
JP2000500973A (ja) 2000-02-02
EP0862633A1 (de) 1998-09-09
DE19543553A1 (de) 1997-05-28
EP0862633B1 (de) 2005-02-02
ES2237778T3 (es) 2005-08-01
US6238859B1 (en) 2001-05-29
ATE288489T1 (de) 2005-02-15
CA2236159C (en) 2011-03-22
DE59611189D1 (de) 2005-03-10
CA2236159A1 (en) 1997-05-29
JP4456671B2 (ja) 2010-04-28

Similar Documents

Publication Publication Date Title
ATE288489T1 (de) Vp-antigene des jc-virus
ATE328068T1 (de) Papillomavirus vakzine
DK0688227T3 (da) Fremstilling af humant papillomavirus capsidprotein og viruslignende partikler
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
ATE465178T1 (de) Methoden zur amyloidentfernung mit anti-amyloid- antikörper
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE3787002D1 (de) Synthetische peptide, die zellulaere immunitaet gegen den aids-virus und dessen proteine erzeugen.
TR199801722T2 (xx) Peptit imm�nojenler.
FI913476A7 (fi) Konjugaattirokotteita, jotka sisältävät immunogeenista proteiinia, HIV-tyyppisiä peptidejä ja anionisia ryhmiä
EP0593290A3 (en) Core antigen protein of the hepatitis C virus, as well as diagnostic procedure and set of reagents.
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ATE240743T1 (de) Verfahren und substanzen gegen protozoen
DE60126482D1 (de) Einkettige antikörper gegen eine p53 mutante
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DK0757098T3 (da) Varmebestandig maltosephophorylase, fremgangsmåde til dens fremstilling, bakterier anvendt til dens fremstilling og fremgangsmåder til anvendelse af enzymet
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
ZA984100B (en) Process for the detection of HIV antibodies and antigens used in it.
DE69829174D1 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)
FR2677666B1 (fr) Peptides ou polypeptides immunogenes du virus bvd et virus apparentes, vaccins les incorporant ou les exprimant, procedes et moyens de production y relatifs.
IT8349430A0 (it) Metodo per la produzione di proteine antigeniche specifiche del virusdell'epatite umana a, loro utilizzazione per la produzione di preparazioni farmaceutiche e mezzi diagnostici
FI950253L (fi) Fimbria-antigeenejä, -vasta-aineita, -osoitusmenetelmiä ja -rokotteita